Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Lilian SchwarzDewi VernereyJean-Baptiste BachetJean-Jacques TuechFabienne PortalesPierre MichelAntonio Sa CunhaPublished in: BMC cancer (2018)
ClinicalTrials.gov , NCT02959879 . Trial registration date: November 9, 2016.